Previous close | 32.26 |
Open | 32.25 |
Bid | 22.50 |
Ask | 27.00 |
Strike | 130.00 |
Expiry date | 2024-01-19 |
Day's range | 32.25 - 32.26 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.
Roche (RHHBY) aims to enter the promising and much-in-demand obesity drug market with the acquisition of Carmot Therapeutics, Inc. for $2.7 billion.
Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.